{"id":"https://openalex.org/W103524613","doi":"https://doi.org/10.1182/blood.v122.21.2653.2653","title":"Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)","display_name":"Initial Results Of a Phase II Trial Of Sorafenib Plus Standard Induction In Older Adults With Mutant FLT3 Acute Myeloid Leukemia (AML) (Alliance trial C11001)","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W103524613","doi":"https://doi.org/10.1182/blood.v122.21.2653.2653","mag":"103524613"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.2653.2653","doi":"https://doi.org/10.1182/blood.v122.21.2653.2653","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.2653.2653","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101423957","display_name":"Geoffrey L. Uy","orcid":"https://orcid.org/0000-0002-7809-0996","observed_orcids":["https://orcid.org/0000-0002-7809-0996"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey L. Uy","raw_affiliation_strings":["Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology, Washington University School of Medicine, Saint Louis, MO, USA,","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054315990","display_name":"Ben L. Sanford","orcid":"https://orcid.org/0000-0003-2800-6319","observed_orcids":["https://orcid.org/0000-0003-2800-6319"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ben Sanford","raw_affiliation_strings":["Alliance for Clinical Trials in Oncology Statistics and Data Center, Duke University Medical Center, Durham, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alliance for Clinical Trials in Oncology Statistics and Data Center, Duke University Medical Center, Durham, NC, USA,","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060959458","display_name":"Guido Marcucci","orcid":"https://orcid.org/0000-0002-3983-5908","observed_orcids":["https://orcid.org/0000-0002-3983-5908"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guido Marcucci","raw_affiliation_strings":["Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA,","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079177940","display_name":"Weiqiang Zhao","orcid":"https://orcid.org/0000-0001-6560-2780","observed_orcids":["https://orcid.org/0000-0001-6560-2780"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weiqiang Zhao","raw_affiliation_strings":["The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA,","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007148032","display_name":"Susan Michelle Geyer","orcid":"https://orcid.org/0009-0002-5649-6909","observed_orcids":["https://orcid.org/0009-0002-5649-6909"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Susan Geyer","raw_affiliation_strings":["The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA,","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029311650","display_name":"Heidi D. Klepin","orcid":"https://orcid.org/0000-0002-6262-1123","observed_orcids":["https://orcid.org/0000-0002-6262-1123"]},"institutions":[{"id":"https://openalex.org/I47251452","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724","country_code":"US","type":"education","lineage":["https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heidi D. Klepin","raw_affiliation_strings":["Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA,","institution_ids":["https://openalex.org/I47251452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109344899","display_name":"Bayard L. Powell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I47251452","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724","country_code":"US","type":"education","lineage":["https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bayard L. Powell","raw_affiliation_strings":["Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA,","institution_ids":["https://openalex.org/I47251452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049910941","display_name":"Maria R. Baer","orcid":"https://orcid.org/0000-0002-9499-1348","observed_orcids":["https://orcid.org/0000-0002-9499-1348"]},"institutions":[{"id":"https://openalex.org/I126744593","display_name":"University of Maryland, Baltimore","ror":"https://ror.org/04rq5mt64","country_code":"US","type":"education","lineage":["https://openalex.org/I126744593"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria R. Baer","raw_affiliation_strings":["Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA,","institution_ids":["https://openalex.org/I126744593"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005939966","display_name":"Wendy Stock","orcid":"https://orcid.org/0000-0002-8349-9200","observed_orcids":["https://orcid.org/0000-0002-8349-9200"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Stock","raw_affiliation_strings":["Hematology/Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA,","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard M. Stone","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA,","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072420982","display_name":"Richard A. Larson","orcid":"https://orcid.org/0000-0001-9168-3203","observed_orcids":["https://orcid.org/0000-0001-9168-3203"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard A. Larson","raw_affiliation_strings":["University of Chicago, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5007148032","https://openalex.org/A5054315990"],"corresponding_institution_ids":["https://openalex.org/I2799885155","https://openalex.org/I4210126298"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.9467,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.76796569,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"122","issue":"21","first_page":"2653","last_page":"2653"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9319999814033508},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.7929999828338623},{"id":"https://openalex.org/keywords/flt3-tkd-mutation","display_name":"FLT3-TKD mutation","score":0.8569999933242798},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9779999852180481},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.9819999933242798},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.7129999995231628},{"id":"https://openalex.org/keywords/daunorubicin","display_name":"daunorubicin","score":0.996999979019165},{"id":"https://openalex.org/keywords/consolidation-therapy","display_name":"consolidation therapy","score":0.5519999861717224},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/allogeneic-hematopoietic-stem-cell-transplantation","display_name":"allogeneic hematopoietic stem cell transplantation","score":0.890999972820282},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6269999742507935},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.6269999742507935},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.7630000114440918},{"id":"https://openalex.org/keywords/therapy-related-aml","display_name":"therapy-related AML","score":0.7689999938011169}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8216556310653687},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.7979450225830078},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6168190836906433},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.5479351282119751},{"id":"https://openalex.org/C2776611710","wikidata":"https://www.wikidata.org/wiki/Q16888295","display_name":"Induction chemotherapy","level":3,"score":0.5376997590065002},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.521621823310852},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.5091094374656677},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4906719923019409},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4495474398136139},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.42510148882865906},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.331768274307251},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.2653.2653","doi":"https://doi.org/10.1182/blood.v122.21.2653.2653","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.2653.2653","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.7599999904632568}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2979807092","https://openalex.org/W2581732250","https://openalex.org/W2565672408","https://openalex.org/W2883443104","https://openalex.org/W2541252438","https://openalex.org/W2979327768","https://openalex.org/W2575877163","https://openalex.org/W2551174814","https://openalex.org/W2538514731","https://openalex.org/W2890696863"],"abstract_inverted_index":{"Abstract":[0],"Sorafenib":[1,35],"is":[2,84,303,379,396,585],"an":[3,29,427,601],"oral":[4,215,513],"multikinase":[5],"inhibitor":[6],"that":[7,127],"blocks":[8],"the":[9,24,48,128,139,178,182,304,309,351,364,400,521,537,553,560],"autophosphorylation":[10],"and":[11,58,115,134,169,205,371,384,493,515,531,600],"activation":[12,179],"of":[13,16,50,74,108,112,118,130,142,181,197,261,308,314,347,354,412,430,437,462,470,562,576,591,596],"a":[14,44,103,150,171,174,226,324,407,434,457,548,588],"number":[15],"tyrosine":[17,26],"kinases;":[18],"it":[19],"has":[20,36],"potent":[21],"activity":[22,37],"against":[23,38],"FLT3":[25,75,321,327,340,566],"kinase":[27,183],"with":[28,40,61,82,99,145,162,187,214,272,345,368,373,426,477,545,583,587],"internal":[30],"tandem":[31],"duplication":[32],"mutation":[33,176],"(FLT3-ITD).":[34],"AML":[39,66,83,97,165,491,546,584],"FLT3-ITD":[41,100,172,310,369],"mutations":[42,76,322,328,567],"as":[43],"single":[45],"agent":[46],"in":[47,59,156,177,331],"setting":[49],"post-transplant":[51],"relapse":[52],"(Metzelder":[53],"et":[54,68,121],"al.,":[55,69,122],"Blood":[56,123],"2009)":[57],"combination":[60],"chemotherapy":[62,94,195,579],"for":[63,95,280,293,300,320,339,445,542,565,580,610],"newly":[64,163],"diagnosed":[65,164],"(Ravandi":[67],"JCO":[70],"2010).":[71,124],"The":[72,297,335,376,392,418,440,574],"prevalence":[73],"among":[77,520],"older":[78,96,143,316,543,581],"adults":[79,317,544,582],"(>60":[80],"years)":[81],"not":[85,224,422],"yet":[86],"well":[87],"defined.":[88],"Historical":[89],"CALGB":[90],"results":[91],"using":[92],"standard":[93],"patients":[98,144,157,358,464],"have":[101,361,405,455],"shown":[102],"complete":[104],"remission":[105,571],"(CR)":[106],"rate":[107,420,442,590],"67%,":[109],"median":[110,336,377,393],"survival":[111,117,141,307],"0.8":[113],"yrs,":[114],"1-yr":[116],"30%":[119],"(Whitman":[120],"We":[125,148],"hypothesized":[126],"addition":[129,575],"sorafenib":[131,216,238,273,286,577,609],"to":[132,234,250,359,454,501,569,578],"induction":[133,459,475,572],"post-remission":[135],"therapy":[136],"would":[137],"improve":[138],"overall":[140,306],"FLT3-mutated":[146],"AML.":[147,611],"conducted":[149],"multicenter,":[151],"single-arm":[152],"phase":[153],"2":[154,264,281,505],"study":[155,302,535],"\u2265":[158],"60":[159,207,483],"years":[160,381,390,448],"old":[161],"(including":[166],"therapy-related":[167],"AML)":[168],"either":[170],"or":[173,189,409,496],"point":[175],"loop":[180],"domain":[184],"(FLT3-TKD).":[185],"Subjects":[186],"PML-RARA":[188],"CBF":[190],"leukemias":[191],"were":[192,233,248,318,329,387,415,487,499,504],"excluded.":[193],"Induction":[194],"consisted":[196,260],"cytarabine":[198,263],"100":[199],"mg/m2":[200,208],"CIVI":[201],"on":[202,210,220,230,242,269,277,363],"days":[203,211,221,243,270,278,469],"1-7":[204],"daunorubicin":[206],"IV":[209],"1-3":[212],"(7+3)":[213],"400":[217,239,274,287],"mg":[218,240,275,288],"bid":[219,241,276,289],"1-7.":[222,244],"Those":[223],"achieving":[225,246],"hypoplastic":[227],"bone":[228],"marrow":[229],"day":[231],"14":[232],"receive":[235],"5+2":[236],"plus":[237],"Patients":[245],"CR":[247,408],"encouraged":[249],"undergo":[251],"allogeneic":[252],"HSCT":[253],"if":[254],"possible.":[255],"For":[256],"all":[257],"others,":[258],"consolidation":[259],"intermediate-dose":[262],"g/m2":[265],"over":[266],"3":[267],"hours":[268],"1-5":[271],"1-28":[279],"cycles.":[282,296],"Following":[283],"consolidation,":[284],"maintenance":[285],"was":[290,342,443],"administered":[291],"daily":[292],"12":[294],"28-day":[295],"primary":[298],"endpoint":[299],"this":[301],"1-year":[305],"patients.":[311],"A":[312],"total":[313],"459":[315],"screened":[319],"though":[323],"central":[325],"laboratory.":[326],"identified":[330],"81":[332],"subjects":[333,425],"(17.6%).":[334],"turn-around":[337],"time":[338,353],"testing":[341],"46":[343],"hours,":[344],"99.1%":[346],"cases":[348],"returned":[349],"within":[350,467,482,552],"cutoff":[352],"48":[355],"hours.":[356],"Fifty-two":[357],"date":[360],"enrolled":[362],"study,":[365],"including":[366,526],"37":[367],"(71%)":[370],"15":[372],"FLT3-TKD":[374],"(29%).":[375],"age":[378],"67":[380],"(range,":[382],"60-83)":[383],"19":[385],"pts":[386,451],">":[388],"70":[389],"(37%).":[391],"follow":[394],"up":[395],"4.5":[397],"months.":[398],"Of":[399],"52":[401,463],"evaluable":[402,524],"patients,":[403,525],"36":[404],"achieved":[406],"CRi":[410,416],"(69%)":[411],"which":[413],"4":[414,518],"(8%).":[417],"CR/CRi":[419,441],"did":[421],"differ":[423],"between":[424],"ITD":[428],"(26":[429],"37,":[431],"70%)":[432],"vs":[433],"TKD":[435],"(10":[436],"15,":[438],"67%).":[439],"58%":[444],"those":[446,488],">70":[447],"old.":[449],"Eight":[450],"are":[452],"known":[453],"received":[456],"second":[458],"course.":[460],"Four":[461],"(8%)":[465],"died":[466],"30":[468],"starting":[471],"their":[472],"most":[473],"recent":[474],"course":[476],"no":[478,494],"additional":[479,495],"deaths":[480],"occurring":[481],"days.":[484],"Treatment-related":[485],"toxicities":[486,498],"typical":[489],"during":[490,598],"induction,":[492,599],"unexpected":[497],"attributed":[500],"sorafenib.":[502],"There":[503],"grade":[506,517],"5":[507],"nonhematologic":[508],"adverse":[509],"events":[510,519],"(lung":[511],"infection;":[512],"mucositis)":[514],"7":[516],"first":[522,538],"40":[523],"infection,":[527],"cardiac,":[528],"respiratory,":[529],"metabolic,":[530],"kidney":[532],"injury.":[533],"This":[534],"represents":[536],"prospective":[539],"clinical":[540],"trial":[541],"targeting":[547],"specific":[549],"mutational":[550],"profile":[551],"US":[554],"cooperative":[555],"group":[556],"setting.":[557],"It":[558],"demonstrates":[559],"feasibility":[561],"rapid":[563],"screening":[564],"prior":[568],"initial":[570],"chemotherapy.":[573],"associated":[586],"high":[589],"CR,":[592],"relatively":[593],"low":[594],"risk":[595],"mortality":[597],"acceptable":[602],"toxicity":[603],"profile.":[604],"Disclosures:":[605],"Off":[606],"Label":[607],"Use:":[608]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-06-24T00:00:00"}